BIOMAT Database Logo BIOMAT Database Logo

Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. 1990

C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
Department of Psychiatry, Innsbruck University Hospital, Austria.

Akathisia is a frequent and distressing side effect of antipsychotic medication. Little is known about its pathophysiology. Treatment trials of serotonin antagonists in Parkinson's disease and neuroleptic-induced Parkinsonism have been disappointing, with the possible exception of akathisia which has been reported to respond favorably to ritanserin. We report first results of a single-blind trial of ritanserin in the treatment of neuroleptic-induced akathisia. Ten patients received a mean dose of 13.5 mg/day (SD +/- 5.8) ritanserin for 2 to 4 days. Treatment response was assessed by the Hillside Akathisia Scale (HAS). HAS baseline ratings were 16.4 (+/- 6). After 3 days of treatment, these values dropped to 7.4 (+/- 5.2). This amelioration was statistically significant (p = .0069 matched-pairs signed rank test). Two patients did not respond. These results, although preliminary in nature, are encouraging and warrant further studies.

UI MeSH Term Description Entries
D008297 Male Males
D010880 Piperidines A family of hexahydropyridines.
D011595 Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions. Agitation, Psychomotor,Akathisia,Excitement, Psychomotor,Restlessness,Psychomotor Hyperactivity,Psychomotor Restlessness,Hyperactivity, Psychomotor,Psychomotor Excitement,Restlessness, Psychomotor
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012702 Serotonin Antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. 5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D016713 Ritanserin A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure. 6-(2-(4-(Bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-7-methyl-5H-thiazolo(3,2-a)pyrimidin-5-one,R-55667,Ritanserin Hydrochloride,Ritanserin Tartrate,R 55667,R55667

Related Publications

C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study.
March 1999, The British journal of psychiatry : the journal of mental science,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
Treatment of neuroleptic-induced akathisia with the 5-HT2A antagonist trazodone.
January 2003, Clinical neuropharmacology,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
December 1990, Clinical neuropharmacology,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
The 5-HT2 antagonist ritanserin decreases sleep in cats.
January 1993, Sleep,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
Ritanserin, a 5-HT2 receptor antagonist, does not modify ECT-induced prolactin release.
January 1990, Psychopharmacology,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia.
November 1999, International clinical psychopharmacology,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
Study of the 5-HT2 antagonist ritanserin on sleep-walking cycle in the rat.
January 1992, Pharmacology, biochemistry, and behavior,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease.
January 1992, Clinical and experimental neurology,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
The pharmacologic treatment of neuroleptic-induced akathisia.
October 1990, Journal of clinical psychopharmacology,
C H Miller, and W W Fleischhacker, and H Ehrmann, and J M Kane
The pharmacologic treatment of neuroleptic-induced akathisia.
February 1990, Journal of clinical psychopharmacology,
Copied contents to your clipboard!